Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.

Quantum-Si Inc. (QSI) reported Q2 2026 revenue of $344,000, above an analyst estimate of $305,020. Diluted EPS was -$0.11, slightly better than expected. The company posted gross profit of $172,000 and an operating loss of $25.6 million, with net loss of $23.5 million. Cash was $23.7 million. Shares fell 1.19% after the release.

Quantum-Si (Nasdaq: QSI) reported Q2 2026 revenue of $344k during the Platinum-to-Proteus transition, down from $591k a year earlier. It updated the Proteus launch to Q2 2027, cut about 20% of staff, and expects annualized operating expense savings of about $12m. Cash runway extends to Q4 2028; cash and investments were $169.9m at June 30, 2026.

Quantum-Si Inc (QSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new mark

Quantum-Si Inc. (QSI) faces a second Nasdaq delisting risk after its Class A shares closed below $1 for 30 straight business days, according to a July 24 SEC filing. Shares traded around 78 cents, down about 29% YTD. Nasdaq gives until Jan. 19, 2027 to regain compliance. Q1 revenue was $258,000 and net loss $21.7 million.

Eli Lilly's shares rose 1% after data showed its oral treatment, Foundayo, achieved greater weight and blood-sugar reductions than oral semaglutide in a 52-week study. The findings were presented at the European Association for the Study of Diabetes meeting. The data is not from a direct head-to-head trial.